| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| |
|
For the Three Months Ended
July 31, |
|
|
For the Nine Months Ended
July 31, |
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Net Income/(Loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,618,860 |
) |
|
$ |
(417,502 |
) |
|
$ |
(4,025,354 |
) |
|
$ |
(1,542,865 |
) |
| Cancer Vaccines |
|
|
(1,464,323 |
) |
|
|
(178,738 |
) |
|
|
(3,033,026 |
) |
|
|
(544,605 |
) |
| Anti-Viral Therapeutics |
|
|
(1,262,260 |
) |
|
|
(281,098 |
) |
|
|
(2,052,821 |
) |
|
|
(590,602 |
) |
| Cancer Diagnostics |
|
|
(38,198 |
) |
|
|
(1,693,304 |
) |
|
|
(60,569 |
) |
|
|
(5,162,977 |
) |
| Patent Licensing |
|
|
(3,969 |
) |
|
|
(6,145 |
) |
|
|
114,894 |
|
|
|
(10,303 |
) |
| Total |
|
$ |
(4,387,610 |
) |
|
$ |
(2,576,787 |
) |
|
$ |
(9,056,876 |
) |
|
$ |
(7,851,352 |
) |
| Net Income/(Loss) |
|
$ |
(4,387,610 |
) |
|
$ |
(2,576,787 |
) |
|
$ |
(9,056,876 |
) |
|
$ |
(7,851,352 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
4,388,236 |
|
|
$ |
2,435,969 |
|
|
$ |
9,571,149 |
|
|
$ |
7,735,975 |
|
| Less non-cash share-based compensation |
|
|
(3,187,326 |
) |
|
|
(1,041,799 |
) |
|
|
(5,224,697 |
) |
|
|
(3,173,219 |
) |
Operating costs and expenses
excluding non-cash share-based
compensation |
|
$ |
1,200,910 |
|
|
$ |
1,394,170 |
|
|
$ |
4,346,452 |
|
|
$ |
4,562,756 |
|
Operating costs and expenses excluding
non-cash share-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
411,313 |
|
|
$ |
189,589 |
|
|
$ |
1,903,707 |
|
|
$ |
759,752 |
|
| Cancer Vaccines |
|
|
348,535 |
|
|
|
72,968 |
|
|
|
1,185,060 |
|
|
|
238,297 |
|
| Anti-Viral Therapeutics |
|
|
418,285 |
|
|
|
155,224 |
|
|
|
826,716 |
|
|
|
376,242 |
|
| Cancer Diagnostics |
|
|
20,645 |
|
|
|
971,698 |
|
|
|
37,368 |
|
|
|
3,180,511 |
|
| Patent Licensing |
|
|
2,132 |
|
|
|
4,691 |
|
|
|
393,601 |
|
|
|
7,954 |
|
| Total |
|
$ |
1,200,910 |
|
|
$ |
1,394,170 |
|
|
|
4,346,452 |
|
|
$ |
4,562,756 |
|
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
1,200,910 |
|
|
$ |
1,394,170 |
|
|
|
4,346,452 |
|
|
$ |
4,562,756 |
|
| |
|
July 31,
2021 |
|
|
October 31,
2020 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
12,709,167 |
|
|
$ |
2,988,124 |
|
| Cancer Vaccines |
|
|
10,706,026 |
|
|
|
946,923 |
|
| Anti-Viral Therapeutics |
|
|
12,849,445 |
|
|
|
2,464,361 |
|
| Cancer Diagnostics |
|
|
682,943 |
|
|
|
2,869,529 |
|
| Patent Licensing |
|
|
114,810 |
|
|
|
184,027 |
|
| Total |
|
$ |
37,062,391 |
|
|
$ |
9,452,964 |
|
| Total assets |
|
$ |
37,062,391 |
|
|
$ |
9,452,964 |
|
|